In early results “unprecedented in rectal cancer,” 14/14 patients show clinical complete response to dostarlimab

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

All fourteen rectal cancer patients in a small phase II study of dostarlimab, an anti-PD-1 monoclonal antibody, saw their cancer completely disappear—with no progression or recurrence at follow-up six to 25 months later. None of the patients required further chemotherapy, radiation, or surgery. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Alice Tracey
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Alice Tracey
Reporter

Login